Baxter Healthcare has notified us that global supply constraints due to manufacturing issues are affecting the following medicines:
- Endoxan (cyclophosphamide) 2 g (as monohydrate) powder for injection vial
- Holoxan (ifosfamide) 2 g powder for injection vial.
These medicines are used to treat various types of cancer. Cyclophosphamide is also used to treat some diseases of the immune system, and to prevent rejection of organ transplants.
The shortages are expected to continue until the end of June 2026.
We have approved the supply of multiple overseas-registered cyclophosphamide and ifosfamide injection products in various strengths under section 19A of the Therapeutic Goods Act 1989 to reduce the impact of these shortages.
Go to About the cyclophosphamide and ifosfamide injection shortages for more information about the shortages, including details of the overseas-registered products and how to obtain them.
The Section 19A approvals database and the Medicine shortage reports database also provide up-to-date information about these products and the shortages (search by the active ingredient).